Industry Blog
5 Reasons In Vitro Toxicology Has Replaced Animal Testing in Cosmetics Safety
For R&D, formulation, and regulatory professionals evaluating their safety testing programs, the shift toward in vitro methods is no longer a trend. It’s the established standard. 1. Regulatory frameworks have
6 Microbial Testing Standards Every Cosmetic and OTC Manufacturer Needs to Understand
Whether you are testing raw materials, in-process samples, or finished goods, the right compendial method depends on your product type, formulation, and regulatory market. Here’s a working overview. 1. USP
6 Ways CPT℠ Labs Consulting Services Strengthen Your Regulatory and Quality Programs
Regulatory complexity within the OTC drug, cosmetic, and dietary supplement space is intensifying. Here’s how CPT℠ Labs’ consulting services help manufacturers and brands get ahead of it. 1. FDA compliance
5 Steps to a Rigorous Hair Care Clinical Study and Why Each One Matters
Hair care claims require clinical backing. Here’s how a well-structured study moves from planning to publishable data. 1. Planning: the decisions made before data collection determine study quality. Clinical study
7 SPF Testing Red Flags Every Sunscreen Brand Should Know Before a Recall Happens
Sunscreen brands are under more scrutiny than ever. Between FDA scrutiny, retailer expectations, consumer watchdog testing, class-action lawsuits, and viral social media callouts, inaccurate SPF claims can quickly turn into
Your Questions Answered: What Is HDRS Testing and Why Does It Matter?
Your Questions Answered: What Is HDRS Testing and Why Does It Matter? Hybrid Diffuse Reflectance Spectroscopy (HDRS) is one of the most significant advances in sunscreen testing in decades, and
The Due Diligence Playbook: How to Qualify Suppliers, CMOs, and Contract Labs for OTC Drug Products
In the OTC drug industry, your product is only as good as the partners who help you make it. The raw material supplier who sources your active pharmaceutical ingredient (API),
Why Supply Chain Quality Management Is Non-Negotiable for OTC Drug Manufacturers
If you’re involved in the manufacture or distribution of over-the-counter (OTC) drug products in the United States, you’re already operating in one of the most scrutinized regulatory environments in the
MoCRA in 2026 Made Simple
MoCRA in 2026: Where Things Stand and What You Should Have Done Yesterday When the Consolidated Appropriations Act of 2023 was signed into law on December 29, 2022, it ushered
Top 3 Takeaways from Our “Launching an OTC Product” Webinar
Bringing an Over-the-Counter (OTC) drug to market is a high-stakes endeavor. If you missed our live webinar about Launching an OTC Product the Right Way, here are the three most